Review

Allergen Immunotherapy in Pediatric Asthma: A Pragmatic Point of View

Michele Miraglia Del Giudice 1, Amelia Licari 2, Ilaria Brambilla 2, Maria Angela Tosca 3 and Giorgio Ciprandi 4, *

1 Department of Woman, Child and of General and Specialized Surgery, University of Campania “Luigi Vanvitelli”, 80100 Naples, Italy; michele.miragliadelgiudice@unicampania.it
2 Department of Pediatrics, Pediatrics Clinic, Ospedale San Matteo, University of Pavia, 27100 Pavia, Italy; a.licari@smatteo.pv.it (A.L.); i.brambilla@smatteo.pv.it (I.B.)
3 Department of Pediatrics, Allergy Center, Istituto G. Gaslini, 16100 Genoa, Italy; mariangelatosca@gaslini.org
4 Allergy Clinic, Casa di Cura Villa Montallegro, 16100 Genoa, Italy

* Correspondence: gio.cip@libero.it

Received: 2 April 2020; Accepted: 2 June 2020; Published: 8 June 2020

Abstract: To date, the only disease-modifying treatment strategy for allergic rhinitis and asthma is allergen immunotherapy (AIT). There is evidence that AIT improves allergic rhinitis and asthma, such as reducing symptom severity and medication use and improving of quality of life, with a long-lasting effect after the end of the course. The recent clinical trials evidenced AIT effectiveness and safety in allergic asthma. Consequently, the current version of the GINA (Global Initiative for Asthma) guidelines recommend AIT as an add-on therapy for asthma. There is also evidence that AIT may exert preventive activity on the possible progression from allergic rhinitis to asthma in children and the onset of new sensitizations. The present review provides a pragmatic summary of the clinical indications of AIT in pediatric asthma, including the immunological mechanisms, the predictive biomarkers, and the safety issues in clinical practice.

Keywords: allergen-specific immunotherapy; subcutaneous immunotherapy; sublingual immunotherapy; allergic asthma; children

1. Introduction

At present, allergen-specific immunotherapy (AIT) remains the only curative treatment of allergic disorders. This therapeutic approach uses administration of the causal allergen to improve specific IgE-mediated response, thereby controlling symptoms. AIT has been used for over a century. AIT is still the only disease-modifying treatment strategy for allergic diseases, as it induces a long-lasting immunological and clinical tolerance toward the causal allergen [1]. For this reason, the most important worldwide regulatory authorities, such as the Food and Drug Administration (FDA) and European Medicines Agency (EMA), have approved AIT.

Subcutaneous immunotherapy (SCIT) and sublingual immunotherapy (SLIT) are the most used and accepted routes of administration and are effective for both adults and children with respiratory allergies such as allergic rhinitis (AR) and asthma [2,3]. SCIT was initially employed with the first description by Leonard Noon [4]. However, SCIT is still limited by the need for frequent injections over a minimum of 3 years, periodic visits to the doctor’s office, and, overall, the potential occurrence of severe systemic reactions. Consequently, there is agreement about the practice that SCIT should only be administered in an adequate medical setting, and clinicians should be trained to manage anaphylactic side effects [1]. The risk of SCIT systemic reaction is higher in uncontrolled asthma and with rush schedules [5]. Therefore, SLIT could be a reliable alternative to SCIT, mainly in children, as, at home,
self-administration is possible, and severe systemic reactions are reduced [6–8]. In clinical practice, the route choice depends on several factors, including product availability or approval, geographic location, cost, patient’s characteristics, physician attitude, and patient preference [9].

The current products for SCIT or SLIT cannot be compared because of their heterogeneous composition and allergen concentration given by different manufacturers [10].

There is evidence that both SCIT and SLIT induce superimposable immunologic effects [11]. Rough allergen extracts are used for SCIT, and there are also chemically modified allergens (allergoids). SLIT is available as an aqueous solutions or tablets. Pending harmonized and international rules to regulate AIT products, there are two situations: distribution as “named patient products” (NPP), which only require to be prepared in compliance with Good Manufacturing Practice, or formal marketing authorization [12]. According to EMA directives, SLIT tablets for grass pollen and house dust mites (HDM) have been approved [13,14].

Thanks to mechanisms providing allergen tolerance, effective AIT may affect the natural history of allergy, preventing new sensitizations and clinical worsening, such as a progression from allergic rhinitis to asthma. Moreover, AIT controls allergic symptoms when not responsive to avoidance or pharmacotherapy, reduces medication use, improves the quality of life, and has long-lasting effects after the end of treatment [15]. The most recent clinical trials strengthened the evidence concerning the AIT effectiveness and safety to treat allergic asthma with SLIT as an add-on therapy [3]. Furthermore, AIT has effects preventing asthma in AR subjects, mainly if started early in childhood [16].

2. Overview of the Mechanisms of Allergen Immunotherapy

The targets of AIT, including both SCIT and SLIT, are the immune response consequent to the causal allergen exposure. Modulating immune response, AIT regulates T- and B-cell changes, immunoglobulin class decreases mediator release, and migration of eosinophils, basophils, and mast cells to inflamed tissues [17–19].

AIT-induced immunologic tolerance is based on the upregulation of allergen-specific T-regulatory (Treg) cells and B-regulatory (Breg) cells, and the consequent down-regulation of the T helper 2 (Th2) response [19] (Table 1).

Table 1. Mechanisms of immunologic tolerance mediated by T and B regulatory cells during allergen immunotherapy.

| Treg-Mediated Mechanisms                                                                 |
|----------------------------------------------------------------------------------------|
| release regulatory cytokines (IL-10, TGF-β, and IL-35)                                 |
| induce tolerant DCs subsets                                                            |
| reduce number of ILC2                                                                  |
| suppress activation of allergen-specific Th2 lymphocytes                               |
| downregulate the expression of FCεRI receptors on mast cells,                         |
| decrease allergen-specific IgE synthesis                                                |
| promote B-cell production of IgG4 antibody                                             |

| Breg-Mediated Mechanisms                                                               |
|----------------------------------------------------------------------------------------|
| release regulatory cytokines (IL-10, TGF-)                                             |
| induce the synthesis of IgG4 blocking antibodies                                       |
| inhibit activation and proliferation of effector T lymphocytes                         |
| suppress Th2-dependent inflammation                                                    |
| promote T-cell expression of Foxp3 and generation of functional Treg cells             |

Breg, B regulatory; DCs, dendritic cells; FCεRI, high-affinity receptor for the Fc region of IgE; Foxp3, forkhead box P3; IgE, immunoglobulin E; IgG4, immunoglobulin G subtype 4; IL, interleukin; ILC2, innate lymphoid cells type 2; TGF, transforming growth factor; Th2, T helper type 2; Treg, T regulatory.

Treg and Breg cells produce interleukin (IL)-10 and transforming growth factor-β (TGF-β), regulatory cytokines inhibiting the activation of allergen-specific Th2 lymphocytes, suppressing type 2 inflammation, and ultimately shifting toward a physiological Type 1-mediated immunity [20].
High-dose AIT induces many immunological modifications: dendritic cells (DCs) produce IL-12, IL-27, and IL-10, which generate and activate distinct phenotypes of Treg cells, in particular, forkhead box P3 (Foxp3)$^+$ Treg and inducible Treg (iTreg) cells [17,19]. Both Foxp3$^+$ Treg and iTreg cells suppress allergic reaction, releasing regulatory cytokines (IL-10, TGF-β, and IL-35), inducing tolerogenic DCs subsets, suppressing allergen-specific Th2 lymphocytes, downregulating the expression of FcεRI receptors on mast cells, decreasing allergen-specific IgE, and promoting IgG4 synthesis [17,19–22]. IL-10 exerts inhibition of IL-4 and IL-5, allergen-specific IgE, but increases IgA and IgG4 [19]. The competitive effect of IgG4 toward IgE antibodies is an “immunologic blockade” that inhibits mast cell and basophil degranulation. TGF-β suppresses Th2 and innate lymphoid cells type 2 (ILC2), thus reducing type 2 inflammation [17,19].

Breg cells promote allergen immune tolerance, by producing IL-10 and TGF-β, blocking IgG4, inhibiting effector T cells, suppressing type 2 inflammation, and restoring allergen-specific Treg cells [21].

3. Clinical Indications of Allergen Immunotherapy in Children with Respiratory Allergy

AIT is indicated in patients suffering from AR with or without conjunctivitis, and/or asthma, after documenting a true allergy to the causal allergen [22]. Candidates for AIT are patients whose symptoms are not controlled adequately by medications and environmental measures or those experiencing unacceptable adverse effects of medications or who wish to reduce the long-term use of medications [23–25].

There is evidence that AIT is effective, safe, and preventive in AR and/or asthma in adults and children, even though there is high heterogeneity among the study populations enrolled, the different schedules, the different AIT products, and the outcomes [6,23–27]. As SLIT is more manageable than SCIT, it has to be preferred in children.

4. Children with Asthma

The prevalence of asthma is about 5–10% in childhood and adolescence [28]. The allergic asthma phenotype is characterized by type 2 inflammation, airway hyperresponsiveness (AHR), and reversible airway obstruction [29]. Asthma control is currently considered the aim of asthma therapy. Asthma management is control-based, such as on a stepwise approach, and gradually titrated [30]. Asthma control is defined as the level to which asthma symptoms are changed by therapy [31–33]. However, it has to be underlined that standard pharmacotherapy is merely symptomatic because it does not affect the underlying pathogenetic mechanisms, as, after its cessation, symptoms and inflammation occur again.

SLIT is recommended as an add-on treatment option in adult asthmatics sensitized to HDM, with comorbid AR, and having exacerbations despite inhaled corticosteroid (ICS) treatment, with forced expiratory volume in 1 s (FEV$_1$) more than 70% predicted, as stated in the latest Global Initiative for Asthma Report (GINA) update [3]. The inclusion of SLIT in HDM was based on a meta-analysis that documented SLIT efficacy in patients with asthma [34]. Moreover, asthma has to be carefully managed throughout the AIT course to prevent uncontrolled asthma [35]. On the other hand, AIT is contraindicated in uncontrolled asthma, as patients with uncontrolled asthma may experience severe adverse reactions [5]. In this context, adding anti-IgE biological therapy (omalizumab) could be a suitable option for increasing the effectiveness and the safety of AIT, particularly in SCIT [35–38].

This significant change in the GINA asthma management strategy draws upon recently published results from a Phase III clinical trial. It evaluated the treatment of HDM allergic asthma with the standardized quality (SQ) HDM SLIT tablet in adults: the addition of HDM SLIT to maintenance therapies improved the requirement for ICS or the time to first exacerbation upon ICS reduction, suggesting that SQ HDM SLIT-tablet treatment may contribute to improving overall asthma control [39,40]. While these data require further studies to assess the long-term efficacy and safety of SQ HDM SLIT in adults, less information is available for adolescents [41,42], and studies are still in
progress in children less than 12 years of age [43]. HDM sensitization in early childhood has been identified as an important risk factor for the development of asthma later in childhood and is associated with impaired lung function in school-age children [44] and persistence of asthma into adulthood [45]. Moreover, sublingual treatment, using 300 index of reactivity (IR)-standardized HDM extract, resulted in improved rhinitis and/or asthma symptoms scores in children aged 6–18 years with AR with or without allergic asthma [46].

There is convincing evidence about the efficacy of AIT in adults and children with allergic asthma, as confirmed by meta-analyses, mainly concerning the impact of SLIT in asthmatic children, even though there were variable results due to the heterogeneity of tested products and clinical outcomes [22,27,47–54]. Combined AR and asthma symptom and medication scores significantly diminished in asthmatic children with comorbid AR after SLIT treatment [48,53,55]. Symptom improvement, reduction in medication use, hospitalizations, emergency department visits, and school absences also persisted after AIT discontinuation. There is evidence that a prospective study showed fewer asthma episodes, the use of relievers, and improved lung function in asthmatic children after 5 years of AIT discontinuation [56]. SCIT was able to control asthma and reduce medication use, including relievers and controllers [49,50,57]. Significant reduction in asthma symptoms, asthma medication use, and airway hyperreactivity in children and adults was reported by meta-analysis [49,50]. These outcomes were confirmed by more pediatric studies [58–61]. SCIT exerts a long-term impact on childhood asthma, as, after a 3-year SCIT, a global remission of asthma was obtained [62]. Moreover, children re-evaluated 9 years after SCIT discontinuation, had a three times lower risk of frequent asthma symptoms than controls [63].

SCIT and SLIT are, therefore, effective in treating AR and asthma in children [64,65]. Notably, AIT could reduce ICS doses, guaranteeing asthma control. AIT added to ICS maintenance therapy reduced ICS doses while still maintaining asthma control in up to 42% of patients [41,61].

5. Patient Selection and Biomarkers of Response

It has to be underlined that AIT is allergen-specific; therefore, a careful workup is mandatory [2]. Major allergens should be identified by molecular diagnostics [66–68]. Benefits and risks, and the ability to comply/cooperate with AIT, should always be assessed [26]. AIT was effective and safe in preschool children [69,70], but there is no agreement about a specific lower age limit [8].

On the other hand, it is a collective experience that some patients are non-responders to AIT. Therefore, the identification and validation of potentially predictive biomarkers of response to AIT is an active field of research. Biomarkers are quantitative measurements that predict clinical and immunological effects of AIT [18,71]. The list includes cellular (Tregs), humoral (allergen-specific IgG₄ (sIgG₄), IgE/IgG₄), molecular (interleukins), and functional (IgE FAB and blocking factor) biomarkers. However, in clinical practice, very few biomarkers are reliable (Table 2). There is evidence that higher levels of sIgE could help predict response to AIT efficacy [72–74].

Regarding the monitoring of AIT efficacy, it has to be considered that the combined assessment of symptom severity and medication use is the most reliable tool [75]. In particular, the visual analog scale could be an easy way to measure the patient’s perception of AIT improvement [76].

As SLIT may be self-administered and is well tolerated, it is more indicated in children.

| Categories                              | Candidate Biomarkers          | Possible Applications                  |
|-----------------------------------------|-------------------------------|---------------------------------------|
| Biomarkers for diagnosis                | Allergen-specific IgE         | Prediction of disease severity         |
| Biomarkers for response prediction      | Allergen-specific IgE (high levels) | and/or progression                     |
| Biomarkers of AIT efficacy              | Symptom score Medication use  | Prediction of patients’ response      |
6. Safety Issue

The safety of AIT has always been a crucial issue in all clinical trials. Many aspects should be considered in clinical practice—an EAACI position paper listed the contraindications to AIT [5]. Moreover, a series of recommendations should carefully comply in clinical practice, as reported in many official documents [77–79]. If AIT is prescribed and administered correctly and prudently, AIT, mainly SLIT, is safe and well-tolerated also in children with allergic asthma. In this regard, SLIT may induce local side effects, including oral itching and swelling, usually self-resolving, in about 30–40% of subjects [77]. Systemic adverse reactions are infrequent in patients treated with SLIT. Therefore, SLIT is preferable in children.

7. New Perspectives

Although AIT is a consolidated therapeutic option, there is room for further insight and investigation in the future. First, as the immune system is plastic in children, early AIT could prevent natural allergy history progression. In this regard, the GAP (Grazax asthma prevention) study provided evidence that five-year SLIT prevented asthma onset in children with allergic conjunctivitis, and, overall, AIT was more effective in younger children [80]. This outcome underlined the concept that AIT should be considered a disease modifier and should be prescribed as soon as possible. The real prevention should be timely. A second issue is a possible synergy with biologics, namely omalizumab. Even though biologics are still indicated in severe asthma, it is conceivable that a high dose of the causal allergen could increase the production of IgE and so raise the risk of an adverse event.

As a consequence, biologics could improve the safety profile of AIT [81,82]. Another aspect is the possible use of IgG4 as a biomarker for assessing the response to AIT. IgG4 is a useful marker of B_{reg} activity and is also commercially valuable. Therefore, serum IgG4 assay could support the clinical evaluation of the AIT response. Last but not least, adherence to AIT is a critical issue, as many patients discontinue this therapy. Different factors can influence this issue, including high cost, duration, frequent medical visits, and poor perception of quick symptom relievers. Patient engagement could be an attractive way to improve AIT adherence [83].

8. Conclusions

AIT is a valuable therapeutic option, especially in childhood, to modify the progression of respiratory allergic disease [84,85]. Both SCIT and SLIT are useful in pediatric allergic asthma, having an intriguing steroid-sparing effect. However, uncontrolled asthma must be a strong contraindication for AIT treatment. However, coupling novel biological therapies with AIT could represent a promising approach to potentially avoiding adverse reactions. At present, AIT should be considered the best expression of personalized medicine in clinical allergy.

Author Contributions: All authors contributed to the study and the writing of the paper. All authors reviewed the manuscript. All authors have read and agreed to the published version of the manuscript.

Funding: This study was not funded.

Conflicts of Interest: All authors declare that they have no financial or non-financial competing interest to disclose that it is relevant to the implementation of this research and this publication.

References
1. Jutel, M.; Agache, I.; Bonini, S.; Burks, A.W.; Calderon, M.; Canonica, W.; Cox, L.; Demoly, P.; Frew, A.J.; O’Hehir, R.; et al. International consensus on allergy immunotherapy. *J. Allergy Clin. Immunol.* 2015, 136, 556–568. [CrossRef] [PubMed]
2. Brozek, J.L.; Bousquet, J.; Agache, I.; Agarwal, A.; Bachert, C.; Bosnic-Anticevich, S.; Brignardello-Petersen, R.; Canonica, G.W.; Casale, T.; Chavannes, N.H.; et al. Allergic Rhinitis and its Impact on Asthma (ARIA) guidelines-2016 revision. *J. Allergy Clin. Immunol.* 2017, 140, 950–958. [CrossRef] [PubMed]
3. Global Initiative for Asthma. GINA Guidelines 2019. Global Strategy for Asthma Management and Prevention. Available online: http://www.ginasthma.org/2019 (accessed on 26 May 2020).

4. Noon, L. Prophylactic inoculation against hayfever. Lancet 1911, 1, 1572. [CrossRef]

5. Pitsios, C.; Demoly, P.; Bili, M.B.; Gerth van Wijk, R.; Pfaar, O.; Sturm, G.J.; Rodriguez del Rio, P.; Tsoumani, M.; Gawlik, R.; Paraskevopoulos, G.; et al. Clinical contraindications to allergen immunotherapy: An EAACI position paper. Allergy 2015, 70, 897–909. [CrossRef]

6. Muraro, A.; Roberts, G.; Halken, S.; Agache, I.; Angier, E.; Fernandez-Rivas, M.; Gerth van Wijk, R.; Jutel, M.; Lau, S.; Pajno, G.; et al. EAACI guidelines on allergen immunotherapy: Executive statement. Allergy 2018, 73, 739–743. [CrossRef] [PubMed]

7. Rodríguez Del Río, P.; Vidal, C.; Just, J.; Tabar, A.I.; Sanchez-Machin, I.; Eberle, P.; Borja, J.; Bubel, P.; Pfaar, O.; Demoly, P.; et al. The European Survey on Adverse Systemic Reactions in Allergen Immunotherapy (EASSI): A pediatric assessment. Pediatr. Allergy Immunol. 2017, 28, 60–70. [CrossRef] [PubMed]

8. Pajno, G.B.; Bernardini, R.; Peroni, D.; Arasi, S.; Martelli, A.; Landi, M.; Passalacqua, G.; Muraro, A.; la Grutta, S.; Fiocchi, A.; et al. Clinical practice recommendations for allergen-specific immunotherapy in children: The Italian consensus report. Ital. J. Pediatr. 2017, 43, 13. [CrossRef] [PubMed]

9. Ciprandi, G.; Cadario, G.; Di Gioacchino, M.; Gangemi, S.; Minelli, M.; Ridolo, E.; Valle, C.; Verini, M.; Boccardo, R.; Incorvaia, C.; et al. Allergist attitude in prescribing specific immunotherapy in polysensitized patients with rhinitis, with evaluation of the treatment effect. J. Biol. Reg. 2009, 23, 165–171.

10. Bauer, C.S.; Rank, M.A. Comparative efficacy and safety of subcutaneous versus sublingual immunotherapy. J. Allergy Clin. Immunol. 2014, 134, 765. [CrossRef]

11. Nelson, H.S.; Makatsori, M.; Calderon, M.A. Subcutaneous Immunotherapy and Sublingual Immunotherapy: Comparative Efficacy, Current and Potential Indications, and Warnings—The United States Versus Europe. Immunol. Allergy Clin. N. Am. 2016, 36, 13–24. [CrossRef]

12. Bonertz, A.; Roberts, G.C.; Hoefnagel, M.; Timon, M.; Slater, J.E.; Rabin, R.L.; Bridgewater, J.; Pini, C.; Pfaar, O.; Akdis, C.; et al. Challenges in the implementation of EAACI guidelines on allergen immunotherapy: A global perspective on the regulation of allergen products. Allergy 2018, 73, 64–76. [CrossRef] [PubMed]

13. EMA. Committee for medicinal products for human use (CHMP). In Proceedings of the Guidance on the Clinical Development of Products for Specific Immunotherapy for the Treatment of Allergic Diseases, London, UK, 20 November 2008.

14. EMA. Committee for medicinal products for human use (CHMP). In Proceedings of the Guidance on Allergen Products Standardization and Quality Issues, London, UK, 20 November 2008.

15. Jutel, M.; Agache, I.; Bonini, S.; Burks, A.W.; Calderon, M.; Canonica, W.; Cox, L.; Demoly, P.; Frew, A.J.; O’Hehir, R.; et al. International Consensus on Allergen Immunotherapy II: Mechanisms, standardization, and pharmacoeconomics. J. Allergy Clin. Immunol. 2016, 137, 358–368. [CrossRef] [PubMed]

16. Halken, S.; Larenas-Linnemann, D.; Roberts, G.; Calderón, M.A.; Angier, E.; Pfaar, O.; Ryan, D.; Agache, I.; Ansotegui, I.J.; Arasi, S.; et al. EAACI guidelines on allergen immunotherapy: Prevention of allergy. Pediatr. Allergy Immunol. 2017, 28, 728–745. [CrossRef]

17. Shamji, M.H.; Durham, S.R. Mechanisms of allergen immunotherapy for inhaled allergens and predictive biomarkers. J. Allergy Clin. Immunol. 2017, 140, 1485–1498. [CrossRef]

18. Berings, M.; Karaaslan, C.; Altunbulakli, C.; Gevaert, P.; Akdis, M.; Bachert, C.; Akdis, C.A. Advances and highlights in allergen immunotherapy: On the way to sustained clinical and immunologic tolerance. J. Allergy Clin. Immunol. 2017, 140, 1250–1267. [CrossRef] [PubMed]

19. Akdis, C.A.; Akdis, M. Mechanisms of allergen-specific immunotherapy and immune tolerance to allergens. World Allergy Organ. J. 2015, 8, 17. [CrossRef]

20. Kappen, J.H.; Durham, S.R.; Veen, H.I.; Shamji, M.H. Applications and mechanisms of immunotherapy in allergic rhinitis and asthma. Ther. Adv. Respir. Dis. 2017, 11, 73–86. [CrossRef]

21. Van de Veen, W.; Wirz, O.F.; Globinska, A.; Akdis, M. Novel mechanisms in immune tolerance to allergens during natural allergen exposure and allergen-specific immunotherapy. Curr. Opin. Immunol. 2017, 48, 74–81. [CrossRef]

22. Huoman, J.; Papapaylou, G.; Pap, A.; Nilsson, L.J.; Jenmalm, M.C. Sublingual Immunotherapy Alters Salivary IgA and Systemic Immune Mediators in Timothy Allergic Children. Pediatr. Allergy Immunol. 2019, 30, 522–530. [CrossRef]
23. Cox, L.; Nelson, H.; Lockey, R.; Calabria, C.; Chacko, T.; Finegold, I.; Nelson, M.; Weber, R.; Bernstein, D.I.; Blessing-Moore, J. Allergen immunotherapy: A practice parameter third update. J. Allergy Clin. Immunol. 2011, 127, S1–S55. [CrossRef]

24. Filipovic, I.D.; Caminati, M.; Kostic, G.; Filipovic, D.; Zivkovic, Z. Allergen-specific sublingual immunotherapy in children with asthma and allergic rhinitis. World J. Pediatr. 2016, 12, 283–290. [CrossRef] [PubMed]

25. Pfaar, O.; Alvaro, M.; Cardona, V.; Hamelmann, E.; Mösges, R.; Kleine-Tebbe, J. Clinical trials in allergen immunotherapy: Current concepts and future needs. Allergy 2018, 73, 1775–1783. [CrossRef]

26. Tang, R.B. House Dust Mite-Specific Immunotherapy Alters the Natural Course of Atopic March. J. Chin. Med. Assoc. 2020, 83, 109–112. [CrossRef] [PubMed]

27. Ricci, G.; Caffarelli, C.; Cangemi, J.; Mastroirili, C.; Giannetti, A. Allergen-specific Immunotherapy for Inhalants Allergens in Children. Curr. Pediatr. Rev. 2020, in press. [CrossRef]

28. Lai, C.K.; Beasley, R.; Crane, J.; Foliaki, S.; Shah, J.; Weiland, S.; ISAAC Phase Three Study Group. Global variation in the prevalence and severity of asthma symptoms: Phase three of the International Study of Asthma and Allergies in Childhood (ISAAC). Thorax 2009, 64, 476–483. [CrossRef]

29. Taylor, D.R.; Bateman, E.D.; Boulet, L.P.; Boushey, H.A.; Casale, T.B.; Chanez, P.; Enright, P.L.; Gibson, P.G.; De Jongste, J.C.; et al. A new perspective on concepts of asthma severity and control. Eur. Respir. J. 2008, 32, 545–554. [CrossRef]

30. Akar-Ghibril, N.; Casale, T.; Custovic, A.; Phijpanonkul, W. Allergic Endotypes and Phenotypes of Asthma. J. Allergy Clin. Immunol. Pract. 2020, 8, 429–440. [CrossRef] [PubMed]

31. Dinakar, C.; Chipps, B.E. Clinical Tools to Assess Asthma Control in Children. Paediatrics 2017, 139, e20163438. [CrossRef]

32. Licari, A.; Marseglia, G.L. Current and future challenges in pediatric severe asthma. Curr. Med. Res. Opin. 2018, 34, 943–944. [CrossRef]

33. Tsabouri, S.; Mavroudi, A.; Feketea, G.; Guibas, G.V. Subcutaneous and Sublingual Immunotherapy in Allergic Asthma in Children. Front. Pediatr. 2017, 5, 82. [CrossRef]

34. Licari, A.; Marseglia, A.; Caimmi, S.; Castagnoli, R.; Foiadelli, T.; Barberi, S.; Marseglia, G.L. Omalizumab in children. Paediatr. Drugs 2014, 16, 491–502. [CrossRef] [PubMed]

35. Rice, J.L.; Diette, G.B.; Suarez-Cuervo, C.; Brigham, E.P.; Lin, S.Y.; Ramanathan, M.; Robinson, K.A.; Azar, A. Allergen-Specific Immunotherapy in the Treatment of Pediatric Asthma: A Systematic Review. Pediatrics 2018, e20173833. [CrossRef] [PubMed]

36. Licari, A.; Castagnoli, R.; Bottino, C.; Marseglia, A.; Marseglia, G.; Ciprandi, G. Emerging drugs for the treatment of perennial allergic rhinitis. Expert Opin. Emerg. Drugs 2016, 21, 57–67. [CrossRef] [PubMed]

37. Licari, A.; Castagnoli, R.; Brambilla, I.; Marseglia, A.; Tosca, M.A.; Marseglia, G.L.; Ciprandi, G. New approaches for identifying and testing potential new anti-asthma agents. Expert Opin. Drug Discov. 2018, 13, 51–63. [CrossRef] [PubMed]

38. Har, D.; Lee, M.J. Systemic Reaction Rates with Omalizumab, Subcutaneous Immunotherapy, and Combination Therapy in Children with Allergic Asthma. Allergy Asthma Proc. 2019, 40, 35–40. [CrossRef] [PubMed]

39. Virchow, J.C.; Backer, V.; Kuna, P.; Prieto, L.; Nolte, H.; Villesen, H.H.; Ljørring, C.; Riis, B.; de Blay, F. Efficacy of a House Dust Mite Sublingual Allergen Immunotherapy Tablet in Adults With Allergic Asthma: A Randomized Clinical Trial. JAMA 2016, 315, 1715–1725. [CrossRef] [PubMed]

40. Mauro, M.; Boni, E.; Makri, E.; Incorvaia, C. Pharmacodynamic and pharmacokinetic evaluation of house dust mite sublingually administered immunotherapy tablet in the treatment of asthma. Expert Opin. Drug Metab. Toxicol. 2015, 11, 1937–1943. [CrossRef]

41. Mosbech, H.; Deckelmann, R.; de Blay, F.; Pastorello, E.A.; Trebas-Pietras, E.; Andres, L.P.; Malcus, L.; Ljørring, C.; Canonica, G.W. Standardized quality (SQ) house dust mite sublingual immunotherapy tablet (ALK) reduces inhaled corticosteroid use while maintaining asthma control: A randomized, double-blind, placebo-controlled trial. J. Allergy Clin. Immunol. 2014, 134, 568–575. [CrossRef]

42. Maloney, J.; Premner, B.M.; Bernstein, D.J.; Lu, S.; Gawchik, S.; Berman, G.; Kaur, A.; Li, Z.; Nolte, H. Safety of house dust mite sublingual immunotherapy standardized quality tablet in children allergic to house dust mites. Ann. Allergy Asthma Immunol. 2016, 116, 59–65. [CrossRef]
43. Lodge, C.J.; Lowe, A.J.; Gurrin, L.C.; Hill, D.J.; Hosking, C.S.; Khalafzai, R.U.; Hopper, J.L.; Matheson, M.C.; Abramson, M.J.; Allen, K.J.; et al. House dust mite sensitization in toddlers predicts current wheeze at age 12 years. *J. Allergy Clin. Immunol.* 2011, 128, 782–788. [CrossRef]

44. Illi, S.; von Mutius, E.; Lau, S.; Niggemann, B.; Gruber, C.; Wahn, U.; Multicentre Allergy Study Group. Perennial allergen sensitisation early in life and chronic asthma in children: A birth cohort study. *Lancet* 2006, 368, 763–770. [CrossRef]

45. Ferré, J.; Justicia, J.L.; García, M.P.; Muñoz-Tuduri, M.; Álvà, V. Efficacy of high-dose sublingual immunotherapy in children allergic to house dust mites in real-life clinical practice. *Allergol. Immunopathol.* 2011, 39, 122–127. [CrossRef]

46. Ciprandi, G.; Marseglia, G.L.; Castagnoli, R.; Valsecchi, C.; Tagliacarne, C.; Caimmi, S.; Licari, A. From IgE to clinical trials of allergic rhinitis. *Expert Rev. Clin. Immunol.* 2015, 11, 1321–1333. [CrossRef]

47. Penagos, M.; Passalacqua, G.; Compalati, E.; Baena-Cagnani, C.E.; Orozzo, S.; Pedroza, A.; Canonica, G.W. Meta-analysis of the efficacy of sublingual immunotherapy in the treatment of allergic asthma in pediatric patients, 3 to 18 years of age. *Chest* 2008, 133, 599–609. [CrossRef]

48. Ross, R.N.; Nelson, H.S.; Finegold, I. Efficacy and safety of sublingual immunotherapy in patients, 3 to 18 years of age. *Chest* 2003, 123, 206–210. [CrossRef]

49. Lin, S.Y.; Erekosima, N.; Kim, J.M.; Ramanathan, M.; Suarez-Cuervo, C.; Chelladurai, Y.; Ward, D.; Segal, J.B. Sublingual immunotherapy for the treatment of allergic rhinoconjunctivitis and asthma: A systematic review. *JAMA* 2013, 309, 1278–1288. [CrossRef]

50. Di Rienzo, V.; Marcucci, F.; Puccinelli, P.; Parmiani, S.; Frati, F.; Sensi, L.; Canonica, G.W.; Passalacqua, G. Long-lasting effect of sublingual immunotherapy in children with asthma due to house dust mite: A 10-year prospective study. *Clin. Exp. Allergy* 2003, 33, 206–210. [CrossRef]

51. Dominguez-Ortega, J.; Delgado, J.; Blanco, C.; Prieto, L.; Arroabarren, E.; Cimarra, M.; Henriquez-Santana, A.; Iglesias-Souto, J.; Vega-Chicote, J.M.; Tabar, A.I. Specific allergen immunotherapy for the treatment of allergic asthma: A review of current evidence. *J. Investig. Allergol. Clin. Immunol.* 2017, 27 (Suppl. 1), 1–35. [CrossRef]

52. Roberts, G.; Hurley, C.; Turcanu, V.; Lack, G. Grass pollen immunotherapy as an effective therapy for childhood seasonal allergic asthma. *J. Allergy Clin. Immunol.* 2006, 117, 263–268. [CrossRef]

53. Eng, P.A.; Reinhold, M.; Gnehm, H.P. Long-term efficacy of preseasonal grass pollen immunotherapy in children. *Allergy* 2002, 57, 306–312. [CrossRef]

54. Hedlin, G.; Wille, S.; Browaldh, L.; Hildebrand, H.; Holmgren, D.; Lindfors, A.; Nordvall, S.L.; Lowenstein, H. Immunotherapy in children with allergic asthma: Effect on bronchial hyperreactivity and pharmacotherapy. *J. Allergy Clin. Immunol.* 1999, 103, 609–614. [CrossRef]

55. Zielen, S.; Kardos, P.; Madonini, E. Steroid-sparing effects with allergen-specific immunotherapy in children with asthma: A randomized controlled trial. *J. Allergy Clin. Immunol.* 2010, 126, 942–949. [CrossRef]
62. Stelmach, I.; Sobocińska, A.; Majak, P.; Smejda, K.; Jerzyńska, J.; Stelmach, W. Comparison of the long-term efficacy of 3- and 5-year house dust mite allergen immunotherapy. *Ann. Allergy Asthma Immunol.* 2012, 109, 274–278. [CrossRef]

63. Cools, M.; Van Bever, H.P.; Weyler, J.J.; Stevens, W.J. Long-term effects of specific immunotherapy, administered during childhood, in asthmatic patients allergic to either house-dust mite or to both house-dust mite and grass pollen. *Allergy* 2000, 55, 69–73. [CrossRef]

64. Asamoah, F.; Kakoourou, A.; Dhami, S.; Lau, S.; Agache, I.; Muraro, A.; Roberts, G.; Akdis, C.; Bonini, M.; Cakmak, O.; et al. Allergen immunotherapy for allergic asthma: A systematic overview of systematic reviews. *Clin. Transl. Allergy* 2017, 7, 25. [CrossRef]

65. Kim, J.M.; Lin, S.Y.; Suarez-Cuervo, C.; Chelladurai, Y.; Ramanathan, M.; Segal, J.B.; Erekosima, N. Allergen-specific immunotherapy for pediatric asthma and rhinoconjunctivitis: A systematic review. *Pediatrics* 2013, 13, 1155–1167. [CrossRef]

66. Dramburg, S.; Matricardi, P.M. Molecular Diagnosis of Allergy: The Pediatric Perspective. *Front. Pediatr.* 2019, 7, 369. [CrossRef]

67. Ciprandi, G.; Natoli, V.; Puccinelli, P.; Incorvaia, C. Allergic rhinitis: The eligible candidate to mite immunotherapy in the real world. *Allergy Asthma Clin. Immunol.* 2017, 13, 11. [CrossRef]

68. Ciprandi, G.; Incorvaia, C.; Frati, F.; Italian Study Group. Management of poly-sensitized patient: From molecular diagnostics to bio-molecular immunotherapy. *Exp. Rev. Clin. Immunol.* 2015, 11, 973–976. [CrossRef]

69. Fiocchi, A.; Pajno, G.; La Grutta, S.; Pezzuto, F.; Incorvaia, C.; Sensi, L.; Marcucci, F.; Frati, F. Safety of sublingual-swallow immunotherapy in children aged 3 to 7 years. *Ann. Allergy Asthma Immunol.* 2005, 95, 254–258. [CrossRef]

70. Agostinis, F.; Tellarini, L.; Canonica, G.W.; Falagiani, P.; Passalaqua, G. Safety of sublingual immunotherapy with a monomeric allergoid in very young children. *Allergy* 2005, 60, 133. [CrossRef]

71. Shamji, M.H.; Kappen, J.H.; Akdis, M.; Jensen-Jarolim, E.; Knol, E.F.; Klein-Tebbe, J.; Bohle, B.; Chaker, A.M.; Tili, S.J.; Valenta, R.; et al. Biomarkers for monitoring clinical efficacy of allergen immunotherapy for allergic rhinoconjunctivitis and allergic asthma: An EAACI Position Paper. *Allergy* 2017, 72, 1156–1173. [CrossRef]

72. Tosca, M.A.; Silvestri, M.; Accogli, A.; Rossi, G.A.; Ciprandi, G. Serum specific IgE and allergen immunotherapy in allergic children. *Immunotherapy* 2014, 6, 9–33. [CrossRef]

73. Ciprandi, G. Serum IgE as biomarker for predicting allergen immunotherapy effectiveness. *J. Allergy Clin. Immunol.* 2018, 139, 2029. [CrossRef]

74. Ciprandi, G.; Tosca, M.A.; Silvestri, M. The practical role of serum allergen-specific IgE as potential biomarker for predicting responder to allergen immunotherapy (AIT). *Exp. Rev. Clin. Immunol.* 2014, 10, 321–324. [CrossRef]

75. Ciprandi, G.; Tosca, M.A.; Silvestri, M.; Ricciardolo, F.L.M. Inflammatory biomarkers for asthma endotyping and personalized therapy. *Exp. Rev. Clin. Immunol.* 2017, 13, 715–721. [CrossRef]

76. Ciprandi, G.; Silvestri, M.; Tosca, M.A. Combo-VAS: An integrated outcome for assessing the perception of allergen immunotherapy effectiveness in clinical practice. *Ann. Allergy Asthma Immunol.* 2018, 121, 504–506. [CrossRef]

77. James, C.; Bernstein, D.I. Allergen Immunotherapy: An Updated Review of Safety. *Curr. Opin. Allergy Clin. Immunol.* 2017, 17, 55–59. [CrossRef]

78. Agache, I.; Lau, S.; Akdis, C.A.; Smolinska, S.; Bonini, M.; Caykaytar, O.; Flood, B.; Gajdanowicz, P.; Izuhara, K.; Kalayci, O.; et al. EAACI Guidelines on Allergen Immunotherapy: House Dust Mite-Driven Allergic Asthma. *Allergy* 2019, 74, 855–873. [CrossRef]

79. Mustafa, S.S.; Bingemann, T.; Blue, H.; Conn, K.; Hanley, T.; Ramsey, T.; Ramsey, A. Systemic Reactions to Subcutaneous Immunotherapy: Effects of Dosing and Aeroallergen Content. *Ann. Allergy Asthma Immunol.* 2019, 123, 284–287. [CrossRef]

80. Valovirta, E.; Petersen, T.H.; Piotrowska, T.; Laursen, M.K.; Andersen, J.S.; Sorensen, F.; Klink, R.; Varga, E.; Hutttegger, I.; Agertoft, L.; et al. Results From the 5-year SQ Grass Sublingual Immunotherapy Tablet Asthma Prevention (GAP) Trial in Children With Grass Pollen Allergy. *J. Allergy Clin. Immunol.* 2018, 141, 529–538. [CrossRef]

81. Porcaro, F.; Cutrera, R.; Pajno, G.B. Options of immunotherapeutic treatments for children with asthma. *Expert Rev. Respir. Med.* 2019, 13, 937–949. [CrossRef]
82. Konstantinou, G.N.; Kaitalidou, E.; Skoulikaris, N. Sublingual immunotherapy and omalizumab cured allergic chronic rhinosinusitis and asthma: Coincidence or synergistic effect? *Ann. Allergy Asthma Immunol.* 2019, 123, 440–443. [CrossRef]

83. Barello, S.; Palamenghi, L.; Graffigna, G. The Mediating Role of the Patient Health Engagement Model on the Relationship Between Patient Perceived Autonomy Supportive Healthcare Climate and Health Literacy Skills. *Int. J. Environ. Res. Public Health* 2020, 17, 1741. [CrossRef]

84. Tosca, M.A.; Licari, A.; Olcose, R.; Marseglia, G.L.; Sacco, O.; Ciprandi, G. Immunotherapy, and Asthma in Children. *Front. Pediatr.* 2018, 6, 231. [CrossRef] [PubMed]

85. Tosca, M.A.; Olcose, R.; Licari, A.; Ciprandi, G. Allergen immunotherapy, and asthma. *Ped. Allergy Immunol.* 2020, 31 (Suppl. 24), 46–48. [CrossRef] [PubMed]

© 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).